Aim immunotech bolsters intellectual property estate for ampligen® with issuance of two key u.s. patents

Extends certain exclusive u.s. rights to ampligen for cancer and me/cfs through 2039 management discusses patent issuance and what this means in a brief video: here ocala, fla., nov. 28, 2023 (globe newswire) -- aim immunotech inc. (nyse american: aim) (“aim” or the “company”) today announced that the u.s. patent and trademark office (uspto) has issued u.s. patent no.
AIM Ratings Summary
AIM Quant Ranking